Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Large Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 602,285 shares, an increase of 289.0% from the June 15th total of 154,817 shares. Approximately 12.9% of the shares of the company are sold short. Based on an average trading volume of 18,970,380 shares, the short-interest ratio is presently 0.0 days.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology at the end of the most recent reporting period. Institutional investors own 1.42% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Friday, May 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Creative Medical Technology currently has a consensus rating of “Reduce”.

Creative Medical Technology Trading Down 0.4%

Shares of CELZ stock traded down $0.00 during trading hours on Tuesday, hitting $0.85. The company’s stock had a trading volume of 113,817 shares, compared to its average volume of 1,586,582. The business has a fifty day moving average of $1.94 and a 200-day moving average of $1.99. Creative Medical Technology has a twelve month low of $0.79 and a twelve month high of $6.25. The stock has a market cap of $4.03 million, a price-to-earnings ratio of -0.40 and a beta of 1.89.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. On average, equities analysts expect that Creative Medical Technology will post -1.14 EPS for the current fiscal year.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.